A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study - PubMed (original) (raw)
Comparative Study
A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study
Jackie A Cooper et al. Atherosclerosis. 2005 Jul.
Abstract
We have compared the predictive value of the PROCAM and Framingham risk algorithms in healthy UK men from the Second Northwick Park Heart Study (NPHS-II) (50-64 years at entry), followed for a median of 10.8 years for coronary heart disease (CHD) events. For PROCAM, the area under the receiver operating characteristic (ROC) curve was 0.63 (95% CI, 0.59-0.67), and not significantly different (p = 0.46) from the Framingham score, 0.62 (0.58-0.66). Sensitivities for a 5% false-positive rate (DR(5)) were 13.8 and 12.4%, respectively. Calibration analysis for PROCAM gave a ratio of observed to expected events of 0.46 (Hosmer-Lemeshow test, p < 0.0001) and 0.47 for Framingham (p < 0.0001). Using measures taken at 5 years of high-density lipoprotein cholesterol and (estimated) low-density lipoprotein cholesterol levels increased the ROC by only 1%. An NPHS-II risk algorithm, developed using a 50% random subset, and including age, triglyceride, total cholesterol, smoking status, and systolic blood pressure at recruitment, gave an ROC of 0.64 (0.58-0.70) with a DR(5) of 10.7% when applied to the second half of the data. Adding family history and diabetes increased the DR(5) to 18.4% (p = 0.28). Adding lipoprotein(a) >26.3 mg/dL (relative risk 1.6, 1.1-2.4) gave a DR(5) of 15.5% (p = 0.55), while adding fibrinogen levels (relative risk for 1S.D. increase = 1.5, 1.1-2.0) had essentially no additional impact (DR(5) = 16.9%, p = 0.95). Thus, the PROCAM algorithm is marginally better as a risk predictor in UK men than the Framingham score, but both significantly overestimate risk in UK men. The algorithm based on NPHS-II data performs similarly to those for PROCAM and Framingham with respect to discrimination, but gave an improved ratio of observed to expected events of 0.80 (p = 0.01), although no score had a high sensitivity. Any novel factors added to these algorithms will need to have a major impact on risk to increase sensitivity above that given by classical risk factors.
Similar articles
- Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation.
Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, Sega R, Pilotto L, Palmieri L, Giampaoli S; CUORE Project Research Group. Ferrario M, et al. Int J Epidemiol. 2005 Apr;34(2):413-21. doi: 10.1093/ije/dyh405. Epub 2005 Jan 19. Int J Epidemiol. 2005. PMID: 15659467 - Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease.
Vrentzos GE, Papadakis JA, Ganotakis ES, Paraskevas KI, Gazi IF, Tzanakis N, Nair DR, Mikhailidis DP. Vrentzos GE, et al. Int J Clin Pract. 2007 Oct;61(10):1643-53. doi: 10.1111/j.1742-1241.2007.01527.x. Int J Clin Pract. 2007. PMID: 17877651 - Predicting the risk of coronary heart disease I. The use of conventional risk markers.
Dent TH. Dent TH. Atherosclerosis. 2010 Dec;213(2):345-51. doi: 10.1016/j.atherosclerosis.2010.06.019. Epub 2010 Jun 16. Atherosclerosis. 2010. PMID: 20637467 Review. - HDL-cholesterol and cardiac disease: which table to use?
Bayly G. Bayly G. Ann Clin Biochem. 2002 Jan;39(Pt 1):12-21. doi: 10.1258/0004563021901667. Ann Clin Biochem. 2002. PMID: 11853184 Review.
Cited by
- Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkhäuser M. Lippuner K, et al. Eur Spine J. 2012 Dec;21(12):2407-17. doi: 10.1007/s00586-012-2404-y. Epub 2012 Jun 28. Eur Spine J. 2012. PMID: 22739699 Free PMC article. Review. - [Primary prevention of coronary heart disease : Evidence-based drug treatment].
Mühleck F, Laufs U. Mühleck F, et al. Herz. 2020 Feb;45(1):39-49. doi: 10.1007/s00059-019-04873-3. Herz. 2020. PMID: 31822926 German. - Association of a sequence variant in DAB2IP with coronary heart disease.
Harrison SC, Cooper JA, Li K, Talmud PJ, Sofat R, Stephens JW, Hamsten A; HIFMECH Consortium; Sanders J, Montgomery H, Neil A; Simon Broome Research Consortium; Humphries SE. Harrison SC, et al. Eur Heart J. 2012 Apr;33(7):881-8. doi: 10.1093/eurheartj/ehr075. Epub 2011 Mar 28. Eur Heart J. 2012. PMID: 21444365 Free PMC article. - Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.
Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M; Working Group 2. Currier JS, et al. Circulation. 2008 Jul 8;118(2):e29-35. doi: 10.1161/CIRCULATIONAHA.107.189624. Epub 2008 Jun 19. Circulation. 2008. PMID: 18566319 Free PMC article. No abstract available. - Genetics of coronary artery disease in the 21st century.
Roberts R, Stewart AF. Roberts R, et al. Clin Cardiol. 2012 Sep;35(9):536-40. doi: 10.1002/clc.22002. Epub 2012 May 15. Clin Cardiol. 2012. PMID: 22588700 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources